“We think we now have tools to measure changes to tumors that have become resistant to therapy,” says HUGEN’s ADRIAN LEE, who identified a new genetic change in the estrogen receptor that hinders treatment of breast cancer in some patients, uncovering new clues for potential improved treatments for breast cancer patients.
MEDICAL X-PRESS - "At least 18 percent of individuals with pancreatic cancer and a personal history of other HBOC- or LS-related cancers carry mutations in a pancreatic cancer susceptibility gene based on our data, suggesting that criteria for genetic testing in individuals with pancreatic cancer should include consideration of previous cancer history," concludes HUGEN's BETH DUDLEY and colleagues.
HEALTH NEWS DIGEST - The current movement in breast cancer research is matching DNA with targeted therapies and HUGEN's ADRIAN LEE is at the forefront. "We know now that no two cancers are alike...the concept is, with our ability to more comprehensively understand the genetic basis of the disease, we can more precisely understand the disease, and then treat the disease and/or predict risk."
STREET INSIDER - Human genetic’s JERRY VOCKLEY, principal investigator on the program, noted, “I am very excited about our Phase 2 and other clinical results showing the near elimination of hypoglycemia and reduction in cardiomyopathy, addressing two of the major life-threatening symptoms in these disorders. A reduction in the frequency of rhabdomyolysis episodes will also greatly improve the lives of our patients. I look forward to continue work...
UPMC/PITT HEALTH SCIENCES NEWSROOM - Public health and dental medicine geneticists from the University of Pittsburgh found that at least 49 genes underlie earlobe attachment. What does this research mean and why is it important?
POST-GAZETTE - “We think we have the cure for the looming superbug epidemic,” DIETRICH STEPHAN recalled the 41-year-old entrepreneur saying. “I said, ‘Oh, really. Send us all your stuff.’” The introduction paid off. Steckbeck’s company, Oakland-based Peptilogics Inc., recently closed on a $5.5 million Series A financing round led by Facebook Inc.’s first major investor Peter Thiel. Stephan, a serial entrepreneur and chair of Pitt Public Health’s ...
CURE - “New technology is allowing us to find cancers that may have a (previously unknown) infectious origin,” says PATRICK MOORE, professor of infectious diseases, microbiology, molecular genetics, and biochemistry. He is credited with co-discovering viral links to two types of skin cancer: Kaposi sarcoma and Merkel cell carcinoma.
POST-GAZETTE - Serial entrepreneur and human genetics chair DIETRICH STEPHAN will serve as CEO of Pitt's new business accelerator, backing a push to leverage Western PA’s strengths in the life sciences with private investors. The 10-year goal is to tackle prevalent and intractable global diseases. The initial focus will be on cancer, Alzheimer’s, multidrug-resistant bacterial infections, obesity, diabetes, and rare genetic diseases.
POPULAR SCIENCE - Geneticists often don’t like to perform population studies at such scale because they are too large to zoom in on any specific details. But that means that we might not be getting the full picture. Research by JOHN SHAFFER, ELEANOR FEINGOLD, and SETH WEINBERG tells us that there’s power in numbers. Just as seemingly simple traits reveal their true complexity, diseases that currently puzzle us will soon become easier to understan...
MIMS TODAY - “Treatability may not be the only consideration people have regarding such information,” says LISA PARKER, a HUGEN researcher who directs Pitt’s Centre for Bioethics and Health Law.